Clinical trial Recruiting at 1 site Observational Ages 18 to 80

How TIPS may improve muscle loss in cirrhosis and the role of FGF21

Official title: Mechanism of Transjugular Intrahepatic Portosystemic Shunt to Improve Sarcopenia by Down-regulation of FGF21

Run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · NCT06794853 · Data updated 2026-11-12

This project tests whether TIPS helps people with cirrhosis regain muscle and whether blood FGF21 levels explain that improvement.

More Cirrhosis trials

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment132 (estimated)
SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Academic / other
Locations1 site (Wuhan)
StatusRecruiting
StartedJune 1, 2025
Main results expectedDecember 1, 2027
Study endsDecember 2027
Registry record updatedFebruary 11, 2026
Trial IDNCT06794853 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–80 with diagnosed liver cirrhosis who are scheduled for TIPS and can give informed consent are ideal candidates.

Probably not a fit

Patients with active malignancy, recent major surgery or trauma, serious cardiovascular/cerebrovascular disease, cognitive impairment, or on certain immune‑suppressing treatments are excluded and may not benefit from the findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with cirrhosis undergoing TIPS will be followed and divided into groups based on whether their sarcopenia improves after the procedure. Blood samples will be collected over time to measure serum FGF21 while imaging and functional tests will track muscle mass, strength, and performance. The study will compare changes in FGF21 and clinical muscle measures between patients who improve and those who do not. The combined value of FGF21 and muscle function indicators will be analyzed for predicting outcomes after TIPS.

Why it matters

Potential benefit: If successful, the study could identify a blood marker and mechanism linking TIPS to muscle recovery, helping clinicians predict who will benefit and tailor post‑TIPS care.

How similar studies have gone: Previous clinical reports have shown TIPS can improve muscle mass and function in some cirrhotic patients, but the mechanism and the role of biomarkers like FGF21 remain largely unproven.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Diagnosed with liver cirrhosis and needing TIPS surgical treatment;
2. Aged between 18-80 years old;
3. Able to understand and sign the informed consent form and willing to cooperate in completing the examinations and follow-up visits.

Exclusion Criteria:

1. Combination of serious cardiovascular and cerebrovascular diseases (such as acute myocardial infarction, severe heart failure, etc.);
2. Suffering from malignant tumors and in the active stage;
3. Recent (within 3 months) history of major surgeries or traumas;
4. The presence of mental illness or cognitive disorders, which are unable to cooperate with the study;
5. Undergoing other special treatments that may affect the results of the study (such as certain specific immune-suppressing agents, hormones, etc.)

Where it's running

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Taiwan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.